Table 2

Kaplan-Meier estimates for the proportion of patients in each group diagnosed with each outcome in at least one quarter during the eight-quarter follow-up, and in at least two quarters

	COVID-19		Other respiratory infection		Control
	Incidence	95% CI	Incidence	95% CI	Incidence	95% CI
Post-COVID
One quarter or more	14.22	13.99 to 14.45	0.00	0.00 to 0.00	0.00	0.00 to 0.00
Two quarters or more	6.73	6.54 to 6.92	0.00	0.00 to 0.00	0.00	0.00 to 0.00
Chronic fatigue syndrome
One quarter or more	1.57	1.48 to 1.65	0.59	0.49 to 0.69	0.27	0.24 to 0.30
Two quarters or more	0.61	0.55 to 0.67	0.13	0.09 to 0.17	0.07	0.06 to 0.09
Fatigue
One quarter or more	13.26	12.99 to 13.54	9.19	8.80 to 9.57	5.96	5.79 to 6.12
Two quarters or more	3.20	3.02 to 3.37	1.74	1.54 to 1.93	0.96	0.88 to 1.04
Dyspnoea
One quarter or more	9.89	9.67 to 10.11	5.09	4.80 to 5.37	3.22	3.10 to 3.34
Two quarters or more	2.70	2.55 to 2.84	0.99	0.86 to 1.12	0.59	0.54 to 0.64
Pulmonary embolism
One quarter or more	0.40	0.36 to 0.44	0.22	0.17 to 0.27	0.24	0.21 to 0.27
Two quarters or more	0.22	0.19 to 0.26	0.11	0.07 to 0.15	0.11	0.09 to 0.13
Psychological disorder
One quarter or more	14.79	14.44 to 15.13	12.81	12.29 to 13.33	9.40	9.17 to 9.63
Two quarters or more	6.87	6.59 to 7.16	6.39	5.95 to 6.83	4.03	3.86 to 4.21
Sense of taste/smell
One quarter or more	3.18	3.07 to 3.30	1.22	1.09 to 1.35	0.50	0.44 to 0.55
Two quarters or more	0.60	0.55 to 0.66	0.16	0.11 to 0.21	0.04	0.03 to 0.06
Mild cognitive impairment
One quarter or more	0.39	0.34 to 0.43	0.18	0.13 to 0.22	0.31	0.28 to 0.35
Two quarters or more	0.16	0.14 to 0.18	0.08	0.05 to 0.12	0.19	0.16 to 0.22
Myalgia
One quarter or more	3.92	3.77 to 4.06	3.41	3.20 to 3.63	2.29	2.19 to 2.38
Two quarters or more	0.91	0.83 to 0.99	0.74	0.63 to 0.85	0.46	0.42 to 0.51